Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism
Andrzej Pilc, Agata Machaczka, Paweł Kawalec, et al.
Expert Opinion on Drug Discovery (2022) Vol. 17, Iss. 10, pp. 1131-1146
Closed Access | Times Cited: 17

Showing 17 citing articles:

Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment
Jenessa N. Johnston, Bashkim Kadriu, Josh Allen, et al.
Neuropharmacology (2023) Vol. 226, pp. 109422-109422
Open Access | Times Cited: 32
Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments
John H. Krystal, Alfred P. Kaye, Sarah Jefferson, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 49
Open Access | Times Cited: 30
(R)-(-)-Ketamine: The Promise of a Novel Treatment for Psychiatric and Neurological Disorders
Hana Shafique, Julie Demers, Julia Biesiada, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 12, pp. 6804-6804
Open Access | Times Cited: 9
Clinical pharmacological innovation in the treatment of depression
Jeffrey M. Witkin, Lalit K. Golani, Jodi L. Smith
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 4, pp. 349-362
Closed Access | Times Cited: 13
Is there a continued need for behavioral pharmacology in the discovery and development of medicines?
Jeffrey M. Witkin, Jodi L. Smith, Daniel P. Radin
Journal of Pharmacology and Experimental Therapeutics (2025), pp. 103571-103571
Closed Access
A Comprehensive Review of the Current Status of the Cellular Neurobiology of Psychedelics
Blerida Banushi, Vince Polito
Biology (2023) Vol. 12, Iss. 11, pp. 1380-1380
Open Access | Times Cited: 12
Postsynaptic Proteins at Excitatory Synapses in the Brain—Relationship with Depressive Disorders
Sylwia Samojedny, Ewelina Czechowska, Patrycja Pańczyszyn-Trzewik, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 19, pp. 11423-11423
Open Access | Times Cited: 17
Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system
Shigeyuki Chaki, Mai Watanabe
Neuropharmacology (2022) Vol. 223, pp. 109348-109348
Closed Access | Times Cited: 16
Psychedelics for treatment resistant depression: are they game changers?
Michail Kalfas, Rosie H. Taylor, Dimosthenis Tsapekos, et al.
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 18, pp. 2117-2132
Open Access | Times Cited: 8
Elucidating genetic and molecular basis of altered higher-order brain structure-function coupling in major depressive disorder
Haixia Long, Zihao Chen, Xinli Xu, et al.
NeuroImage (2024) Vol. 297, pp. 120722-120722
Open Access | Times Cited: 2
Depression and the Glutamate/GABA-Glutamine Cycle
Mortimer Mamelak
Current Neuropharmacology (2024) Vol. 23, Iss. 1, pp. 75-84
Closed Access | Times Cited: 2
3,4-Dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide analogs act as potential AMPA receptor potentiators with antidepressant activity
Long wei, Xueyu Qi, Xueli Yu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 251, pp. 115252-115252
Closed Access | Times Cited: 6
Treatment response with ketamine in chronic suicidality: An open label functional connectivity study
Adem Can, Daniel F. Hermens, Abdalla Z. Mohamed, et al.
Journal of Affective Disorders (2023) Vol. 331, pp. 92-100
Closed Access | Times Cited: 5
Advances in Antidepressant Therapy: Comparing the Efficacy of Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), and Novel Agents
Amber Nawaz, Beena Mamoon, Tashbiha E Batool, et al.
Cureus (2024)
Open Access | Times Cited: 1
Potential use of psilocybin drugs in the treatment of depression
Katarzyna Śladowska, Paweł Kawalec, Tomasz Brzostek, et al.
Expert Opinion on Emerging Drugs (2023) Vol. 28, Iss. 4, pp. 241-256
Closed Access | Times Cited: 2
Intranasal LAG3 antibody infusion induces a rapid antidepressant effect via the hippocampal ERK1/2-BDNF signaling pathway in chronically stressed mice
Yunli Fang, Hainan Pan, Hao‐Jie Zhu, et al.
Neuropharmacology (2024) Vol. 259, pp. 110118-110118
Closed Access
QSPR modeling to predict surface tension of psychoanaleptic drugs using the hybrid DA-SVR algorithm
Meriem Ouaissa, Maamar Laidi, Othmane Benkortbi, et al.
Journal of Molecular Graphics and Modelling (2024) Vol. 134, pp. 108896-108896
Closed Access
Page 1

Scroll to top